Pocket Program - CROI

Recommendations

Info

Building B Georgia World Congress Center Level Three Breakout Rms B308 B313 Overflow Rms B310 B311 Level Two Media Ctr B202 Speaker Svcs/Poster Drop-off B208 CROI Headquarters B211 Level One Breakout Rm Hall B1 Poster Hall Hall B2 CyberCafe Hall B2 First Aid Level Five Breakout Rms Ballroom 1-2 Ballroom 3-4 Level Four Breakout Rms B402 B406 Overflow Rms B403 B404 Registration Lobby Message Center Lobby Coat Check Lobby Street Entrance to Bldg B Registration Message Ctr Terrace Restaurant Escalators Up to Ballroom Level Five Coat Check B308 B202 Media Ctr Escalators Elevators B310 Overflow for B308 285 International Blvd NW, Atlanta, GA 30313 CROI Message Center 404-222-5800 Ballroom 1-2 Hall B1 General Session Speaker Svcs/ Poster Drop-off + B402 Escalators Escalators Elevators Escalators B311 Overflow for B313 B313 Elevators Elevators Escalators Escalators B208 Escalators B211 HQ Escalators Escalators CyberCafe Elevators Ballroom 3-4 Elevators Escalators Down to Level Four Hall B2 Poster Hall Coffee breaks B403 B404 Overflow for B402 Overflow for B406 B406 Escalators Elevators Escalators
POSTER SESSIONS Poster Hall open from 7 am to 7 pm; all posters will be available for viewing for the duration of the conference 53. HIV Persistence, Reservoirs, and Viremic Control 55. Envelope/Entry/Tropism/Transmission 58. Assembly–Putting It All Together 59. Restriction Factors: Old and New 64. HIV Compartments 67. HIV Infection Models 71. Immune Restoration 73. Immune Activation/Function in HIV Infection 74. Immune Activation, T Cell Homeostasis, and Therapy 75. Mucosal Factors in HIV Transmission and Infection 77. HIV Compartmentalization and Evolution on Therapy 84. Progressive Multifocal Leukoencephalopathy and Other Central Nervous System Infections 85. Central Nervous System Penetration, ART Intensification, and Cerebrospinal Fluid Escape 86. ART, Neurocognitive Outcomes, and New Central Nervous System-targeted Therapies 87. Central Nervous System Viral Evolution and Compartmentalization 95. Mining Sequence Data to Understand Transmission and Disease 96. Transmission Clusters 98. Within-patient Diversity Compartmentalization, Dual Infection, and Recombination 100. ARV Pharmacogenetics: Metabolism, Drug Interactions, and Response 101. ARV Drug Exposure, Safety, and Efficacy 105. New ARV Agents 106. Randomized Trials of ART: A Potpourri 118. Hepatic Injury and Fibrosis 119. Laboratory Assessment and Imaging of Hepatic Injury 120. Hepatitis E Virus 121. Hepatitis B Virus 128. HIV-associated Malignancies: Miscellaneous 130. Cardiovascular Disease: Predicting Risk and Monitoring Outcomes 131. Endothelial Dysfunction in HIV Infection 132. Vascular Imaging and Subclinical Atherosclerosis 141. Diabetes, Metabolic Syndrome, and Vitamin D Deficiency 143. Bone Loss: Risk Factors and Pathogenesis 144. ART and Bone Disease 150. Cryptococcal Infections 151. Herpes Zoster 152. Cytomegalovirus–Host Pathogen Interactions 153. Syphilis: Not Gone, Not Forgotten 154. Opportunistic Infections and Other Novel Pathogens 155. Vaccines: TB, Pneumococcus, and Influenza 156. HIV Shedding and Impact of Infection on Immune Cells in Women 161. HIV Testing and ARV Drug Resistance during Pregnancy 162. ART, Viral Suppression, and MTCT 170. Incidence and Prevention of PMTCT-associated Drug Resistance 171. New HIV Infections among Children in the US 172. ART Initiation and Immune Reconstitution Inflammatory Syndrome among Infants and Children 173. ART Strategies and Outcomes among Children 174. Cost and Cost-effectiveness of ART and Monitoring Strategies in Children 178. Characteristics of Youth with HIV 180. ARV Pharmacokinetics in Children 183. Preclinical Studies of Topical ARV for Prevention 187. Voluntary Medical Male Circumcision 190. The Cascade of Care 191. Engagement and Retention in Care 197. Performance and Innovation in ART Programs in RLS 56. Transcription/Reverse and Forward, Splicing/Replication 60. Restriction Factors: APOBEC and Others 62. Shutting the Door on HIV Entry 63. Transmitted/Founder Viruses 66. Markers of HIV Disease Progression 69. CD8 T Cells in HIV Infection 70. Killer T Cells 78. Viral DNA Dynamics 79. Infected Cell Dynamics on Therapy 80. What Is Latency and What Can We Do about It? 82. Novel Vaccine Strategies 88. Neuropathogenesis Mechanisms 89. Central Nervous System Inflammation and Biomarkers of HIV-associated Neurocognitive Disorders 90. Aging and Neurocognitive Function in HIV Infection 94. Simian Viral Reservoirs 97. HIV Subtypes: Epidemiology and Disease Progression 99. New Approaches to ARV Drug Delivery 102. ARV Pharmacokinetics: New Assays, Drugs, and Special Populations 110. Tropism Testing/Maraviroc Resistance 111. HIV Drug Resistance: Trends and Emergence 112. Detecting and Interpreting HIV Drug Resistance 113. Innovation in Measuring Viral Nucleic Acids 114. Transmitted Drug Resistance 115. Drug Resistance Mutational Pathways and Subtype Associations 116. Advances in Sequencing and Analysis 117. Detecting HIV Infection 122. Hepatitis C Virus Treatment Today and Tomorrow 123. Hepatitis C Virus Resistance and Virology 124. Innate Immunity and Hepatitis C Virus 126. Hepatic Failure and Transplantation 127. Emergence and Persistence of HPV-associated Malignancies in the ART Era 133. Statin Use and HIV: How Sweet Is It? 134. Dyslipidemia: Risks, Pathogenesis, and Treatment 135. Risk Prediction, Risk Factors, Biomarkers, and Outcomes 137. Inflammatory Biomarkers, Microparticles, and Clinical Outcomes in HIV 138. ART Effects: Monocyte and T Cell Activation 147. TB Screening Strategies: Diagnostics New and Old and Latent TB Treatment 149. Mechanisms of Immune Reconstitution 157. Hepatitis C Virus Testing in Women 163. ARV Strategies, MTCT, and HIV-free Survival 164. PMTCT Implementation: Barriers and Program Innovations 167. Breast Feeding and Prevention of Postnatal MTCT 168. ARV Pharmacokinetics during Pregnancy and Breast Feeding 169. ARV Regimens and Safety during Pregnancy 175. HIV Drug Resistance in Children and Youth 176. Co-infections among HIV-infected and -exposed Children 184. Non-human Primate Models of STI, PrEP, and Vaccines 186. Implementation and Cost-effectiveness of Male Circumcision 188. The Ongoing Epidemic in MSM 193. Estimating Incidence 194. New Testing Strategies 198. Adherence and Retention in RLS 54. ART, Complications, and TB 57. Accessory Proteins/Gag 61. Macrophage–HIV Interactions: Cell Biology and Treatment 65. HIV Genotypes and Phenotypes 68. HIV and Monocytes, Macrophages, and Dendritic Cells 72. Microbial Translocation 76. Neutralizing Antibodies and How to Stimulate Them 81. Mechanism of HIV Latency and Reactivation 83. Gene and Adoptive Immunotherapy 91. NeuroAIDS Clinical Studies 92. Neuroimaging Studies 93. Human Genomics 103. Compartment Penetration of ARV 104. ARV Drug Interactions 107. ART: Too Early or Too Late? Or Better Late than Never! 108. ART: Host and Viral Determinants of Outcome 109. ART: Care and Adherence 125. Hepatitis C Virus Epidemiology and Clinical Outcomes 129. HIV-associated Malignancies: Lymphoma 136. Microbial Translocation Measurement and Associations 139. ART Effects: Gene Expression and Cellular Function 140. Frailty: From Mice to Men and Women 142. Renal Disease: Diagnosis, Predictors, and Drugs 145. TB: Incidence, Risk Factors, and Outcomes 146. TB Diagnostics 148. The “ART” of TB Treatment 158. HIV Risk Factors, Prevalence, and Barriers to Care 159. Family Planning: Unintended Pregnancy and Unmet Need 160. HIV in Peri- and Post-menopause 165. Pregnancy Complications among HIV + Women 166. PMTCT: Maternal and Child Health Outcomes 177. HIV and ART-related Complications and Treatment in Children and Youth 179. Tenofovir in Children 181. Immune Response to Perinatal HIV 182. Response to Pediatric Vaccines in Children and Youth 185. Oral PrEP and ARV Adherence 189. MSM in the Developing World 192. Disease Progression, Morbidity, and Mortality 195. Biological and Behavioral Transmission Risks 196. Reducing Risk 199. Virologic Failure, 2 nd - and 3 rd -line Therapy in RLS
Page 1 and 2:
Pocket Program CR I 2O13 20th Confe
Page 3 and 4:
vi General Information CROI 2013 AB
Page 5 and 6:
viii General Information CROI 2013
Page 7 and 8:
x Hotel Information CROI 2013 Map K
Page 9 and 10:
CROI 2013 Session 2 j Sunday, 9 am-
Page 11 and 12:
CROI 2013 Session 8 i Monday, 8:30-
Page 13 and 14:
CROI 2013 Session 12 k Monday, 10 a
Page 15 and 16:
CROI 2013 Session 16 b Monday, 1:30
Page 17 and 18:
CROI 2013 Session 20 e Monday, 4-6
Page 19 and 20:
CROI 2013 Session 26 11:00 85 Impac
Page 21 and 22:
CROI 2013 Session 31 1023 Risk Fact
Page 23 and 24:
CROI 2013 Session 34 e Tuesday, 4-6
Page 25 and 26:
CROI 2013 Session 40 i Wednesday, 8
Page 27 and 28:
CROI 2013 Session 45 11:00 153LB Om
Page 29 and 30: CROI 2013 Session 49 1103 Attrition
Page 31 and 32: CROI 2013 Session 52 e Wednesday, 4
Page 33 and 34: CROI 2013 Session 57 188LB Kelly
Page 35 and 36: CROI 2013 Session 65 c Tuesday, 2:3
Page 37 and 38: CROI 2013 Session 70 c Wednesday, 2
Page 39 and 40: CROI 2013 Session 75 329 Impact of
Page 41 and 42: CROI 2013 Session 82 369 Transcrip
Page 43 and 44: CROI 2013 Session 89 413 Risk of Cl
Page 45 and 46: CROI 2013 Session 93 456 A Longitud
Page 47 and 48: CROI 2013 Session 100 c Tuesday, 2:
Page 49 and 50: CROI 2013 Session 106 c Monday, 2:3
Page 51 and 52: CROI 2013 Session 111 c Wednesday,
Page 53 and 54: CROI 2013 Session 117 616 Immigran
Page 55 and 56: CROI 2013 Session 122 656 Compariso
Page 59 and 60: CROI 2013 Session 131 c Monday, 2:3
Page 63 and 64: CROI 2013 Session 144 809 Prevalenc
Page 65 and 66: CROI 2013 Session 150 847 Improving
Page 67 and 68: CROI 2013 Session 161 885 The Impac
Page 69 and 70: CROI 2013 Session 171 + 924 Women
Page 71 and 72: CROI 2013 Session 180 c Wednesday,
Page 73 and 74: CROI 2013 Session 187 994 Protecti
Page 75 and 76: CROI 2013 Session 192 1032b Changes
Page 77 and 78: CROI 2013 Session 197 1074 Alexa
Page 79: CROI 2013 Session 199 nd 1113 -lin
show all

Pocket Program - CROI

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?